Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
BörsenkürzelEOLS
Name des UnternehmensEvolus Inc
IPO-datumFeb 08, 2018
CEOMr. David Moatazedi
Anzahl der mitarbeiter332
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 08
Addresse520 Newport Center Dr Ste 1200
StadtNEWPORT BEACH
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92660-7022
Telefon19492844555
Websitehttps://www.evolus.com/
BörsenkürzelEOLS
IPO-datumFeb 08, 2018
CEOMr. David Moatazedi
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten